Swiss National Bank
APRE icon

Swiss National Bank’s Aprea Therapeutics APRE Stock Holding History

Swiss National Bank’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,060
Closed -$108K – 2643
2021
Q1 		$108K Hold
1,060
– – ﹤0.01% 2481
2020
Q4 		$104K Hold
1,060
– – ﹤0.01% 2490
2020
Q3 		$510K Hold
1,060
– – ﹤0.01% 2354
2020
Q2 		$822K Buy
+1,060
New +$696K ﹤0.01% 2210

Other funds holding APRE

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return

Swiss National Bank's APRE Position: Q2 2021 in Review

Swiss National Bank sold out of Aprea Therapeutics (APRE) in Q2 2021, closing a stake of 1,060 shares — an estimated $108K sold.

Swiss National Bank first reported a position in APRE in Q2 2020 and held it in 4 quarters. The position peaked at $822K in Q2 2020. 50 funds tracked by Wall St. Rank hold APRE as of Q2 2021.

  • Swiss National Bank reported no remaining Aprea Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Swiss National Bank sold 1,060 Aprea Therapeutics shares in Q2 2021, an estimated $108K.
  • Swiss National Bank first reported a position in Aprea Therapeutics in Q2 2020 and held it in 4 quarters.
  • Swiss National Bank's Aprea Therapeutics position peaked at $822K in Q2 2020.
  • 50 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2021.

Based on Swiss National Bank's 13F filing for Q2 2021, filed 6 Aug 2021.